Among the 67 eligible patients, there were 4 with triple-negative, 17 with HER-2-enriched, 7 with luminal A, and 39 with luminal B breast cancer according to the standard devised by the 12th St Gallen International Breast Cancer Conference (2011). Here, ERBB2 is linked to breast carcinoma.